GRFS is off the screens on one check: relative strength.
Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.
Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.
Grifois, S.A. is not on any of the screens right now. Its relative strength rating is 59, and it sits in Pharmaceutical Preparations.
Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.
- Ex-dividendconfirmedin 17dEx-dividend dateDec 3, 2026
On average 4.8% either way across its last 2 reports.
Checking your subscription…
Close before the report day to close after it, so it holds whether the company reported before the open or after the close.
No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.
None of the tracked funds held or sold it in their latest filings.
Nothing flagged for this company on the last market sweep.
No headlines for this company in the last couple of weeks.
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.
Checking your subscription…
No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.
No completed base to compare this one with yet.